[go: up one dir, main page]

MX2011008456A - Anticuerpos anti-mst1r y usos de los mismos. - Google Patents

Anticuerpos anti-mst1r y usos de los mismos.

Info

Publication number
MX2011008456A
MX2011008456A MX2011008456A MX2011008456A MX2011008456A MX 2011008456 A MX2011008456 A MX 2011008456A MX 2011008456 A MX2011008456 A MX 2011008456A MX 2011008456 A MX2011008456 A MX 2011008456A MX 2011008456 A MX2011008456 A MX 2011008456A
Authority
MX
Mexico
Prior art keywords
antibodies
mst1r
disorders
conditions
disclosure
Prior art date
Application number
MX2011008456A
Other languages
English (en)
Inventor
Reimi Kawaida
Toshiaki Ohtsuka
Toshinori Agatsuma
Philip Rodley
Sandra Miller
Ulrike Schubert
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2011008456A publication Critical patent/MX2011008456A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona regiones de enlace a) antígeno recombinante y anticuerpos y fragmentos funcionales que contienen dichas regiones de enlace del antígeno que son específicas para el MST1R, el cual juega un rol integral en diferentes enfermedades o padecimientos tales como el cáncer. Estos anticuerpos, por consiguiente, pueden ser utilizados para tratar estas y otras enfermedades y padecimientos. Los anticuerpos de la descripción también pueden ser utilizados en el campo de los diagnósticos, así como para la investigación adicional del rol del MST1R en el progreso de enfermedades asociadas con tumores. La descripción también proporciona secuencias de ácido nucleico que codifican los anticuerpos anteriores, vectores que contienen los mismos, composiciones farmacéuticas y equipos con instrucciones de uso.
MX2011008456A 2009-02-10 2010-02-10 Anticuerpos anti-mst1r y usos de los mismos. MX2011008456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15141109P 2009-02-10 2009-02-10
PCT/JP2010/052479 WO2010093055A1 (en) 2009-02-10 2010-02-10 Anti-mst1r antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2011008456A true MX2011008456A (es) 2011-09-26

Family

ID=42227811

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008456A MX2011008456A (es) 2009-02-10 2010-02-10 Anticuerpos anti-mst1r y usos de los mismos.

Country Status (19)

Country Link
US (1) US9403909B2 (es)
EP (1) EP2396084B1 (es)
JP (1) JP5714511B2 (es)
KR (1) KR101745025B1 (es)
CN (1) CN102438702B (es)
AU (1) AU2010214301B2 (es)
BR (1) BRPI1007979A2 (es)
CA (1) CA2752136C (es)
CO (1) CO6420322A2 (es)
ES (1) ES2583281T3 (es)
HK (1) HK1164193A1 (es)
IL (1) IL214527A0 (es)
MX (1) MX2011008456A (es)
NZ (1) NZ594452A (es)
RU (1) RU2534890C2 (es)
SG (2) SG2014009195A (es)
TW (1) TWI480050B (es)
WO (1) WO2010093055A1 (es)
ZA (1) ZA201105725B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2841457B1 (en) * 2012-04-27 2019-04-24 Daiichi Sankyo Company, Limited Anti-robo4-antibody
HUE066594T2 (hu) 2015-09-24 2024-08-28 Daiichi Sankyo Co Ltd Anti-GARP antitest
SG11201901597UA (en) * 2016-08-26 2019-03-28 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
CN114222588A (zh) 2019-08-12 2022-03-22 雷杰纳荣制药公司 巨噬细胞刺激1受体(mst1r)变体及其用途
WO2021066751A1 (en) * 2019-10-02 2021-04-08 Aslan Pharmaceuticals Pte. Ltd. Antigen specific binding domains and antibody molecules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
CA2566647A1 (en) 2004-05-13 2005-12-22 Imclone Systems Incorporated Inhibition of macrophage-stimulating protein receptor (ron)
WO2006002025A1 (en) * 2004-06-15 2006-01-05 Nestec S.A. Aerated creamers and processes
WO2006020258A2 (en) * 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
CL2008003449A1 (es) * 2007-11-21 2010-02-19 Imclone Llc Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
CN101977937A (zh) * 2008-01-22 2011-02-16 拜奥根Idec马萨诸塞公司 Ron抗体及其用途

Also Published As

Publication number Publication date
ZA201105725B (en) 2012-04-25
CN102438702A (zh) 2012-05-02
TWI480050B (zh) 2015-04-11
JP2012517223A (ja) 2012-08-02
NZ594452A (en) 2013-01-25
AU2010214301A1 (en) 2011-09-01
AU2010214301B2 (en) 2016-11-10
HK1164193A1 (zh) 2012-09-21
IL214527A0 (en) 2011-09-27
CA2752136A1 (en) 2010-08-19
RU2011137405A (ru) 2013-03-20
JP5714511B2 (ja) 2015-05-07
KR101745025B1 (ko) 2017-06-20
CO6420322A2 (es) 2012-04-16
BRPI1007979A2 (pt) 2017-10-03
RU2534890C2 (ru) 2014-12-10
SG2014009195A (en) 2014-04-28
WO2010093055A1 (en) 2010-08-19
SG173196A1 (en) 2011-08-29
EP2396084A1 (en) 2011-12-21
CN102438702B (zh) 2016-03-02
CA2752136C (en) 2016-03-15
TW201036635A (en) 2010-10-16
KR20110117677A (ko) 2011-10-27
US9403909B2 (en) 2016-08-02
EP2396084B1 (en) 2016-05-11
ES2583281T3 (es) 2016-09-20
US20120034215A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
IN2012DN05175A (es)
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
MY157164A (en) Anti-mesothelin antibodies and uses thereof
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2015016814A (es) Anticuerpo anti-tweakr y sus usos.
NZ754051A (en) Novel antibodies and uses thereof
TW200716674A (en) Anti-GM-CSF antibodies and uses therefor
WO2005103083A3 (en) Anti-cd38 human antibodies and uses therefor
EA201891366A1 (ru) Гуманизированные антитела против cd73
PH12015501284A1 (en) Bcma antigen binding proteins
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501337A1 (en) Substituted pyrrolo-aminopyrimidine compounds
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
EA201492101A1 (ru) Антитела против fcrn
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
PH12015501687A1 (en) Novel binding proteins from pcsk9
WO2014151982A3 (en) Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
AU2017329645A8 (en) Novel antibodies against Factor XI and uses thereof
PH12012501556A1 (en) Substituted naphthalenyl-pyrimidine compounds
WO2013087929A3 (de) Verfahren zur identifizierung von markersequenzen für gynäkologisches malignom
MX2011008456A (es) Anticuerpos anti-mst1r y usos de los mismos.
MX368486B (es) Plantas cucurbitaceas androceas, metodos de obtencion y usos de dichas plantas cucurbitaceas.
WO2011085134A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
NZ724772A (en) Antibodies against hpa-1a

Legal Events

Date Code Title Description
FG Grant or registration